Surrozen (NASDAQ:SRZNW – Get Free Report) is projected to post its results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($1.2880) per share and revenue of $0.4670 million for the quarter.
Surrozen Stock Performance
SRZNW stock opened at $0.01 on Thursday. The business has a 50 day moving average price of $0.01 and a 200 day moving average price of $0.02. Surrozen has a fifty-two week low of $0.00 and a fifty-two week high of $0.05.
Surrozen Company Profile
Surrozen, Inc is a clinical-stage biotechnology company headquartered in South San Francisco, California, focused on the discovery and development of novel therapeutics that harness the Wnt signaling pathway. The company employs a proprietary “surrogate agonist” platform to engineer bispecific antibodies that mimic natural Wnt ligands by concurrently engaging Frizzled receptors and LRP5/6 co-receptors. This approach is designed to promote tissue regeneration and modulate cellular pathways implicated in fibrosis and oncology.
Surrozen’s lead program is advancing in fibrotic disease, where restoring proper Wnt signaling may support the repair of damaged tissues in conditions such as idiopathic pulmonary fibrosis.
Recommended Stories
- Five stocks we like better than Surrozen
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Surrozen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surrozen and related companies with MarketBeat.com's FREE daily email newsletter.
